Daiichi Enters Funded Research Agreement With Cyntellect
Under the terms of the collaboration, Cyntellect will design, configure and run LEAP cell-based assays against a compound collection provided by Daiichi. Specific financial terms were not disclosed.
"We are pleased to establish a formal research relationship with Daiichi, one of Japan's leading pharmaceutical companies," stated Dr. Fred Koller, President and CTO. "Daiichi's commitment to Cyntellect and LEAP represents another important validation of our technology and highlights the unique value proposition presented by combining imaging and cell manipulation in the process of discovering new therapeutics."
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.
Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.